FDA issues final guidance on inhalational anthrax

FDA issues final guidance on inhalational anthrax

(HealthDay)—Final guidance has been issued by the U.S. Food and Drug Administration to assist in the development of drugs for the prevention of inhalational anthrax for individuals who may have been exposed but who have not yet displayed related signs or symptoms.

The FDA's final targets inhalational and revises the indication to "prophylaxis of inhalational anthrax" for the reduction of disease risk among those who have inhaled or are likely to inhale aerosolized Bacillus anthracis spores but who do not yet have established disease. The guidance is a result of efforts to advance the policy framework for development of treatments targeting inhalational anthrax.

Since naturally occurring inhalational anthrax is extremely rare and it would be unethical to expose human volunteers to B. anthracis spores, clinical trials cannot be conducted in humans. The final guidance clarifies that drugs developed for inhalational anthrax prophylaxis can rely on evidence from animal studies (the Animal Rule) to support approval when the criteria under the Animal Rule have been met.

"The FDA encourages developers to reference the final guidance issued today when designing studies to appropriately establish the safety and effectiveness of drugs for prophylaxis of inhalational anthrax," according to the agency's news brief.


Explore further

FDA approves new drug for inhaled anthrax

More information: More Information

Copyright © 2018 HealthDay. All rights reserved.

Citation: FDA issues final guidance on inhalational anthrax (2018, June 1) retrieved 16 September 2019 from https://medicalxpress.com/news/2018-06-fda-issues-guidance-inhalational-anthrax.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more